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Abstract
Severe and poorly controlled asthma still accounts for a great portion of the patients affected. Disease control and
future risk management have been identified by international guidelines as the main goals in patients with asthma.
The need for new treatment approaches has led to reconsider anticholinergic drugs as an option for asthma
treatment. Tiotropium is the first anticholinergic drug that has been approved for children and adults with poorly
controlled asthma and is currently considered as an option for steps 4 and 5 of the Global Initiative for Asthma. In
large randomized clinical trials enrolling patients with moderate to severe asthma, add-on therapy with tiotropium
has demonstrated to be efficacious in improving lung function, decreasing risk of exacerbation and slowing the
worsening of disease; accordingly, tiotropium demonstrated to be non inferior compared to long acting beta-agonists
in the maintenance treatment along with medium to high inhaled corticosteroids. In view of the numerous ancillary
effects acting on inflammation, airway remodeling, mucus production and cough reflex, along with the good safety
profile and the broad spectrum of efficacy demonstrated in different disease phenotypes, tiotropium can represent a
beneficial alternative in the therapeutic management of poorly controlled asthma. The present extensive narrative
review presents the pharmacological and pathophysiological basis that guided the rationale for the introduction of
tiotropium in asthma treatment algorithm, with a particular focus on its conventional and unconventional effects;
finally, data on tiotropium efficacy and safety. from recent randomized clinical trials performed in all age categories will
be extensively discussed.
Keywords: Airway remodeling, Anticholinergic, Asthma, Exacerbation, Forced expiratory flow, Inflammation, Muscarinic
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Background
Asthma is a chronic inflammatory disease of the airways
characterized by a complex pathophysiology and caused
by different etiological factors which contribute to the
heterogeneity of clinical presentation and to the severity
of disease. Asthma can manifest both in childhood and
in elderly patients [1], the number of patients affected
worldwide being estimated in 235 million [2], ranging
from 1 to 18% of the population in different countries
[3]. Asthma is characterized by a variable combination
of symptoms such as wheeze, cough, shortness of breath,
chest tightness and by different degrees of airflow ob-
struction and airway hyper-responsiveness that can vary
in time and intensity [3, 4]. The worsening of respiratory
symptoms and thus disease exacerbations can be caused
by direct or mediated mechanical, physical and infec-
tious stresses that increase bronchial inflammation and
cause an acute worsening of airflow obstruction [3]. The
latter circumstance, especially in elderly patients, can be
complicated by comorbid conditions requiring a multi-
disciplinary therapeutic approach [5, 6]. Poor control of
symptoms and acute exacerbations requiring emergency
room admittance and hospitalization expose patients to
a poor quality of life, high mobility and a significant eco-
nomic burden on the healthcare system and society [7].
Although to a minor extent compared with chronic ob-
structive pulmonary disease (COPD) [8, 9], severe and
poorly controlled asthma still accounts for a significant
in-hospital mortality, especially in children, elderly and
mechanically ventilated patients [10, 11], or patients from
low income countries [2]. For many years, important ef-
forts have been spent to optimize asthma management;
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however, despite the availability of new treatment options
[12], international surveys continue to provide evidence
for suboptimal asthma control in many countries [13],
with poor control of symptoms and exposure to risk of
exacerbation in some cases affecting more than 50% of pa-
tients [14, 15]. The need for new treatment approaches
has led to reconsider anticholinergic drugs as a pharmaco-
logical treatment option for asthma [16]. While also other
muscarinic antagonists are currently being considered for
approval in asthma [16], the only anticholinergic drug in-
troduced so far in the treatment algorithms of major inter-
national guidelines is represented by tiotropium bromide.
In the last few years numerous clinical trials proved the
efficacy of tiotropium both in adult and younger patients
for the chronic treatment of asthma. Due to the numerous
non-bronchodilator properties expressed by tiotropium,
its efficacy may not completely rely on the reduction of
the airways’ cholinergic bronchomotor tone, but also on
anti-inflammatory and modulatory effects of the struc-
tures involved in the complex molecular and cellular
pathophysiology of asthma. The aim of the present exten-
sive narrative review is to highlight the pharmacological
and non-bronchodilator properties of tiotropium and to
present the data of clinical trials conducted so far to
examine its role in connection with the current pharma-
cological treatment paradigm in patients with asthma.
The rationale for anticholinergic drugs in asthma
The cholinergic system in human airways
The innervation of human airways is mainly represented
by the parasympathetic system [17]. The sympathetic
system is less represented, however, some sympathetic
endings can be found on ganglion cell bodies and, there-
fore, may be involved in the modulation of cholinergic
traffic [18, 19]. Acetylcholine (ACh) is the major neuro-
transmitter of the parasympathetic nervous system and
acts both at the ganglionic transmission and the neu-
roeffector junctions [16, 18]. ACh has two classes of
receptors: nicotinic and muscarinic. The first are ligand-
gated ion channels, mainly present on the peribronchial
ganglion; muscarinic receptors are G-protein-coupled
receptors and more widely distributed in the lung [19].
Bronchoconstriction is primarily regulated by muscarinic
receptors (MR); of the five receptor subtypes, M1, M2
and M3 are expressed in the lung and in the bronchial
tree. M1R are mainly distributed in the peripheral lung
tissue and in the alveolar walls [16] within parasympa-
thetic ganglia and regulate cholinergic transmission [20].
M2R are found in post-ganglionic nerves where they
serve as auto-receptors, on smooth muscle cells (SM)
where they are coupled to inhibitory G-proteins [16, 21]
and on fibroblasts [16]. Together with M2R, M3R are the
most represented in human airways; they are predomin-
antly expressed in SM cells and mediate SM ACh-induced
contraction [16, 20]. In central airways this mechanism is
mediated by vagal innervation, in the periphery of the lung
M3R function is mediated by ACh released in response to
inflammatory stimuli from epithelial cells expressing
choline acetyl-transferase (ChAT) [16]. M3R serve also
as mediators of airways blood vessels and can be found
in sub-mucosal glands where they are responsible for
mucus secretion [22].
Although in normal conditions adrenergic sympa-
thetic, cholinergic and non-cholinergic parasympathetic
nerves are all active, vagal innervation is considered the
major determinant of airways’ tone [22] and is regarded
as the major reversible pathophysiological mechanism
responsible for airflow obstruction in COPD. In asthma,
an up-regulated release of ACh causes an increased
bronchial tone, bronchial hyper-responsiveness and re-
flex bronchoconstriction [23] which in turn contribute
to the narrowing of the airways causing respiratory
symptoms and eventually asthma exacerbations. The ac-
curate reason for an increased ACh activity is still un-
known, but it has been postulated to derive from an
increased susceptibility of the cholinergic system, in-
creased intracellular signaling of muscarinic receptors or
by activation of prejunctional facilitatory receptors on
cholinergic nerve endings, leading to up-regulated syn-
thesis through higher activity of ChAT or by reduced
degradation through choline-esterases [24].
In parallel to the vagal-mediated ACh production, the
non-neuronal cholinergic system has an important regu-
latory role in the homeostasis of airway cells. ACh is re-
sponsible for numerous cell vital functions as cell-cycle,
proliferation, differentiation, migration and chemokinesis
[21]. Increasing evidences suggest that in the airways,
non-neuronal ACh can affect several transduction path-
ways such as G-proteins, phospholipase C, effector
kineses, classical and non selective ion and cation chan-
nels, and large conductance voltage and calcium-
activated potassium channels [21]. Although in some
cases cholinergic effects may be produced by mediators
other than ACh on MR [21], almost every cell type
present in the airways expresses components of the
cholinergic system, such as MR, ChAT, the high affinity
choline transporter (CHT-1), as well as ACh itself [24].
Non-neuronal production of ACh could be particularly
relevant in peripheral airways, where cholinergic innerv-
ation is scarce. A production of non-neuronal ACh may
also be responsible, together with the parasympathetic
vagal system, in the modulation of the bronchomotor
tone, both in basal conditions and in a disease-state [21].
Given these evidences, the blockade of MR by cholinergic
antagonists may not always seem beneficial. The effect will
rely mostly on drug’s specific receptor selectivity, kinetics,
dynamics and on the molecules the cholinergic antago-
nists interact with. In asthma, the usual regulatory role of
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M2R can be overcome by eosinophil release during
allergen-challenges, while M2R in some cases can also be
dysfunctional [25]. An increased activation of M3R by ACh
during airway inflammation states has an effect on SM
remodeling, mucus production and the fostering of the in-
flammatory response [26]. Although it is still not clear if
an increased parasympathetic tone is due to the inflam-
matory state present in asthma or represents a patho-
physiological mechanism by itself, the rationale for the
application of cholinergic antagonists in asthma ap-
pears robust [16, 20] and the non-neuronal cholinergic
represents a favorable target.
Unmet needs in asthma
To obtain and maintain disease control, until 2015, long
acting β2-agonists (LABA) represented the only inhaled
bronchodilator treatment in international guidelines,
which recommended a stepwise approach according to
which LABA in association with inhaled corticosteroids
(ICS) at low doses were added beginning from step 3, to
be increased in step 4 and 5 [27, 28]. In the last decade
the paradigm of asthma control has been evolving along
with the increased awareness that any intervention
employed to obtain the disease control should consider
the management of patients’ future risk [29, 30]. The
latter should include, among others, the minimization of
adverse events while providing the optimal treatment
coverage, the prevention of lung function decline and re-
duced lung growth in children and, most importantly,
the prevention of recurrent exacerbation and especially
severe relapses leading to emergency department access
and hospitalization [4, 30]. Major risk factors related to
future exacerbations are represented by a previous history
of exacerbations, increased use of oral corticosteroids and
rescue medications, obesity, worse lung function, poor ad-
herence to inhaled therapy, low Asthma Control Ques-
tionnaire (ACQ-7) score, co-morbid diseases, chronic
sinusitis and cigarette smoke (Table 1) [3, 31–43]. Despite
poor inhaler technique has been demonstrated to be re-
lated to worse asthma control [44, 45], most of the ana-
lyses designed to evaluate risk factors predictive of future
exacerbations did not include it in the regressions [37].
The definition of full control in international guidelines
includes the use of reliever medication less than twice a
week, having no limitation in daily life activities, normal
lung function and absence of nocturnal symptoms [3].
Despite this approach, and the numerous pharmacological
and clinical interventions now available, there is frequently
a misperception of asthma control among patients [40]. In
a recent multicenter European study involving more than
8,000 patients, sub-optimal asthma control was found in
56.2% of patients [38], while in a large cohort of patients
that followed a guideline-derived asthma control manage-
ment [15], although the majority of patients treated with
Table 1 Factors associated with increased risk of poor asthma
control in adults and the pediatric population
Determinants for poor control Pediatric Adults
Clinical and functional
Exacerbations in the previous year
(previous 12 months)
X X
Hospitalizations in the previous year
(previous 12 months)
X X
Respiratory infections (previous 12 months) X
Oral corticosteroid use (previous 12 months) X X
SABA prescriptions (1x200 dose canister/month) X
Healthcare utilization X X
Poor lung function X
Sputum or blood eosinophilia X
Variability of asthma control X X
ACQ-7 < 15 X X
Demographic
Female X
Age (40 to 64 years old) X
Comorbidities
GERD X
Obesity X X
Overweight X
Low birth weight X
OSA-sleep disordered breathing X X
Allergic rhinitis X X
Congestive heart failure X
Drug exposure X
Psychological
Anxiety and depression X
Misperception of disease X X
Low expectations X
Poor knowledge of disease X X
Parent related severity of disease X
Patient-independent
Doctor-related attitudes X
Patient-dependent
Weight gain X
Low adherence X
Poor inhaler technique X
Active and past smoking X
Passive smoking X
As for gender-related risk, different authors demonstrated an association
with poor asthma control and both female and male gender (mild and
severe exacerbations for female gender and higher SABA usage for males).
ACQ-7, Asthma control questionnaire; SABA, Short acting β2 agonists; mo,
months. Data are from [3, 31–43]
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LABA/ICS controller therapy achieved well controlled
asthma, 29% of patients remained poorly controlled.
Moreover, severe asthma exacerbations, often triggered by
viral infections, can occur even in patients with mild
asthma that usually appears well controlled [46]. Although
the role played by poor compliance to inhaled therapy and
the little awareness of the disease severity among patients
[40] has been largely recognized as a weak point in asthma
control, some alternative mechanisms may in part justify
this phenomenon.
Why muscarinic antagonists as add-on therapy in asthma
In the Symbicort Maintenance and Reliever Therapy
(SMART) trial, chronic use of LABA has been related to
a small but significant increase in risk of asthma-related
deaths, especially among African Americans [47], rising
the attention of the American Food and Drug Adminis-
tration (FDA) on the possible role of a step-down ap-
proach of LABA in patients treated with LABA/ICS
fixed dose combination (FDC), especially in asthmatic
children [48–51]. Asthma control, exacerbations [52]
and inflammation can worsen adding LABA to ICS [53].
It has been hypothesized that in asthma, long term use
of LABA not associated with ICSs, is accompanied by
down regulation of β2 adrenoreceptors and thus by
tachyphylaxis [54], with a loss of bronchoprotection
[55, 56] and a reduction in responsiveness to reliever
therapy with salbutamol [57, 58]. A genetic-based sub-
sensitivity of response to LABA/ICS FDC treatment
can also derive from the Arg16/Arg16 β2-receptor
polymorphism, with an increased airway hyper-
responsiveness in affected subjects [59–61]. Moreover,
the efficacy and potency of β2-agonists is gradually re-
duced in presence of increasing concentrations of con-
tractile stimuli, including MR agonists and histamine
both in vitro [62, 63] and in vivo [64]. The effect can
be ascribed to the cross-talk between Gq-coupled
muscarinic M3R or histamine H1 receptors and Gs-
coupled β2-adrenoceptors [65–67]. Another pathway
inducing β2-adrenoceptor desensitization can be me-
diated by β2-agonists involving phosphorylation and
activation of G-protein-coupled receptor kinase 2 [68].
The down regulation and uncoupling of pre-junctional
β2-adrenoreceptors secondary to prolonged LABA
stimulation can increase cholinergic transmission [54],
which acts via M3R and protein-kinase C phosphoryl-
ation. The administration of long acting muscarinic
antagonists (LAMA) can thus counteract both the aug-
mented cholinergic transmission and protect against
LABA induced sub-sensitivity [69].
In this view, the application of antimuscarinic drugs in
asthma had to be expected but was initially largely
underestimated [70]; in fact, although they proved to be
efficacious both in asthma and COPD especially in the
acute setting [71], until a few years ago LAMA and
short acting muscarinic antagonists (SAMA) were not
part of the long term treatment strategy of international
guidelines. This might be attributed to inconsistent re-
sults previously reported with SAMA (atropine and
ipratropium) [72] that proved to be less effective in
terms of acute bronchodilation when compared to sal-
butamol [72], which could be secondary to the lower
drug doses [23] or, more probably, to the poor receptor
selectivity of atropine and ipratropium. In fact, both
anticholinergic molecules are not selective for M3R. An
unselective blockade of M2R, which usually acts as a
pre-synaptic auto-receptor for the blockade of further
release of ACh from nerves to SM cells, can overcome
the M3R antagonism and thus favor bronchoconstric-
tion [23, 73]. The rationale for the combination of
LABA and LAMA in the maintenance therapy in
asthma is also favoured by the interaction between MR
and β2-adrenoceptors in the airways [74]. In fact, ad-
ministration of formoterol has been demonstrated to
induce an upregulation of M3R [75]. The augmented ACh
release secondary to uncoupling of β2-adrenoceptors
during prolonged exposure to LABA might be prevented
by administration of LAMA, which can also prevent
LABA induced sub-sensitivity [54]. The cross-talk be-
tween adrenergic and cholinergic receptors might also jus-
tify a synergistic action of concomitant administration of
LAMA and LABA/ICS therapy, by which LAMA may
protect against adverse molecular effects secondary to
long exposure to LABA [54].
Tiotropium bromide
The anticholinergic alkaloids contained in Atropa
belladonna, Datura stramonium and Hyosciamus niger
plants have been used as popular remedies to alleviate
respiratory symptoms since ancient Egyptians times
and the Middle Ages, when in Europe the deadly
nightshade was used [76]. In the 19th century atropine,
a racemate of hyoscyamine [77], was isolated from
nightshade, and became the progenitor of the modern
anticholinergic compounds such as ipratropium. Since
the '70s there was a renewed interest in anticholiner-
gics as alternative options for the treatment of ob-
structive diseases, but ipratropium bromide, although
demonstrated good clinical efficacy during acute
asthma exacerbations [78], had a short duration of ac-
tion and less bronchodilating effects compared with in-
haled β2-agonists [78]. In the '90s tiotropium bromide
was developed [79]. Tiotropium bromide is a synthetic
quaternary ammonium anticholinergic agent derived
from ipratropium bromide [80] (molecular formula
C19H22BrNO4S2 [81]). Tiotropium demonstrated a high
functional selectivity for specific MR, with a long duration
of action, being approximately 10-fold more potent than
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ipratropium in binding MR in vitro and in vivo studies
[82]. Kinetic studies showed that tiotropium had a high se-
lectivity for M1R and M3R and dissociated 100 times
slower than ipratropium from M1R (14.6 h vs 0.11 h) and
M3R (34.7 h vs 0.26 h) [83]. At the same time it had dis-
sociation time from M2R 10 times faster than from M3R,
making it a selective functional antagonists of M3R [79].
Further labeling and functional in vitro studies on human
lungs confirmed its selectivity over M2R [83]. Tiotropium
is poorly absorbed from the gastro-intestinal tract and has
very low systemic bioavailability [84]. After a single dose
inhalation, peak plasma levels are reached after a max-
imum of 5 min, with a subsequent rapid decline in 1 h to
very low levels (in the 2 pg/mL range) [85]. Tiotropium is
than eliminated with a terminal half-life of 5 to 6 days, in
a dose-dependent manner [85]. In vitro functional studies
demonstrated that, although with a slower onset of action
compared with ipratropium, the offset of tiotropium is
very long compared with atropine, with a half-life of
300 min. These results justify the prolonged inhibitory ef-
fect of tiotropium in pharmacological in vivo studies. In
asthmatic patients treated with tiotropium in doses from
10 to 80 μg, it demonstrated a protection against metha-
choline challenge for up to 48 h [86]; a prolonged and
rapid onset of protection against methacholine challenge
in patients with moderate airway hyper-responsiveness
was later confirmed by Terzano and colleagues [87]. Ana-
lysis of pooled data from phase II and phase III RCTs in
patients with asthma exposed to tiotropium delivered via
Respimat® shows that tiotropium is rapidly absorbed
rapidly, with maximum plasma concentrations 5 min
post-inhalation. Compared with COPD patients, the
peak plasma concentration in patients with asthma was
approximately 52%, with no difference in exposure
comparing the once daily and twice daily administra-
tion regimens. Age, allergic status, race, geographical
region and smoking history did not appeared to influ-
ence the systemic exposure to tiotropium in patients
with asthma [88]. In the numerous randomized clinical
trials conducted in COPD [89], tiotropium showed an
excellent and sustained bronchodilator effect [90], with
proved efficacy in the reduction of static and dynamic
volumes [91], in the reduction of the incidence of acute
exacerbations [90], in the improvement of quality of life
and symptoms [90], together with a good safety profile [91].
Approved for the long-term treatment of COPD since
2002 (2004 in the United States), tiotropium has been
initially delivered via dry powder inhaler at the dosage of
18 μg qd; since 2014, tiotropium has been delivered
also via Respimat® SoftMist™ inhaler technology, with
lowered dosages (5 μg once daily). Following positive
large efficacy and safety trials in asthma, in 2014 the
European Medicines Agency has extended the indica-
tion of tiotropium Respimat® at a dose of 2.5 μg once
daily (delivered in two inhalation of 1.25 μg each) to
patients with asthma, which was also approved in more
than 50 countries, including Japan. In September 2015
the Food and Drug Administration confirmed the same
indication; the latter being extended for patients aged 6
and older since 16th February 2017.
Tiotropium non-bronchodilator effects
The immunopathologic response in asthma involves dif-
ferent inflammatory pathways and cells, mainly eosino-
phils, T-lymphocytes and macrophages which have a
different role and are differently distributed in atopic
and non atopic asthma [92, 93]. The inflammatory re-
sponse is not limited to the migration of inflammatory
cells in the epithelium of the airways, but is also charac-
terized by the modulation and activity of the epithelial
barrier per se, with the involvement of fibroblasts and
smooth muscle cells [94]. As the majority of the involved
cells express muscarinic receptors, the role of the neur-
onal and non-neuronal cholinergic system and thus of
LAMA administration can go far beyond the modulation of
the bronchomotor tone, enhancing the anti-inflammatory
and bronchodilator effects of LABA [95]. We present here
a brief overview of the evidences of tiotropium ancillary
effects in vivo and in vitro.
Airway inflammation
Allergen inhalation, cigarette smoke and exogenous
stresses like methacholine induce inflammatory M3R–
mediated influx of eosinophils and neutrophils in the
airways and are responsible for the production of nu-
merous inflammatory mediator such as IL-8 and IL-6
[96]. However, the role of ACh in remodeling processes
seems to be independent of the allergic inflammatory
response and might be driven directly by bronchocon-
striction, as demonstrated by the allergen-induced in-
flammation in knockout M3R models [16]. Eosinophils
are responsible for M2R dysfunction in the lungs [16],
while ACh is known to mediate the production of
leukotriene-B4 (LTB4) and thus to lead neutrophil re-
cruitment [97]. In animal models of allergic asthma, the
protective effect of Tiotropium against airway hyper-
responsiveness and airway inflammation was shown to
be paralleled by a reduction in the eosinophil depos-
ition in the airways [23, 98]. The authors speculate that
in this case Tiotropium acted through non conventional
pathways, non-neuronal ACh release from macrophages
and epithelial cells or acting directly on M3R present on
eosinophils, although the existence of the latter is to be
confirmed yet. A suppressive activity of tiotropium on the
production of macrophages-derived chemotactic media-
tors has been previously described mostly in COPD
models. In vivo [97] and in vitro [99] studies have demon-
strated a reduction in LTB4-mediated inflammation
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promoted by tiotropium; a reduction in neutrophilic-
mediated inflammation acting on the concentration of
TNF-α, IL-6 and macrophage inflammatory proteins was
also described in smoke induced neutrophilia [100] and in
lipopolysaccharide-induced neutrophilia in a guinea pig
model of COPD [101]. Although leukotriene-E4 inflam-
mation represents a useful biomarker both for asthma
control and treatment management, to date, studies ad-
dressing the potential role of tiotropium in the modula-
tion of leukotriene-E4-induced inflammation in asthma
are lacking. In a rhinovirus infection model of human tra-
cheal cells, Turner and colleagues showed that tiotropium
was able to reduce the viral RNA and cytokine levels in
the supernatant fluid, reducing IL-6, IL-8 and IL-1β levels
[102]. Eosinophilic recruitment was affected also by a con-
comitant administration of tiotropium and budesonide or
ciclesonide in animal models of asthma [103, 104]. Recent
evidences in guinea pig models of asthma demonstrated a
synergistic action between olodaterol and tiotropium
when administered together; in fact, tiotropium supported
and enhanced the protection against allergen-induced
hyper-responsiveness, fully inhibiting the early and late
asthmatic reaction [105]. The latter mechanism may be
explained by the evidence that during charbacol induced
inflammation of human fibroblasts, tiotropium seem to
sustain olodaterol in restoring c-AMP levels in airway
fibroblasts, cooperating to decrease the inflammatory
response [93].
Airway remodeling
Chronic inflammation in asthma drives the pathological
structural remodeling of the airways. M3R mediate air-
way smooth muscle thickening and extracellular matrix
deposition [17]. Previous experiments with fibroblasts
from patients with COPD and active smokers demon-
strated an increased expression of ChAT, M1R and M3R
compared with fibroblasts from healthy controls, associ-
ated with an increased proliferation following Ach ad-
ministration [106], a phenomenon down regulated by
tiotropium and mediated by MR, extracellular signal-
regulated kinase (ERK) 1/2 and nuclear factor (NF) kap-
paB [106]. In cultured fibroblasts and myofibroblasts,
tiotropium was shown to inhibit ACh-induced prolifera-
tion in a concentration-dependent fashion [107] and to
inhibit the production of metallo-proteinases-2 (MMP-2)
while sparing tissue inhibitors of MMP-1 and MMP-2
[108, 109]. Tiotropium also showed an anti-remodeling
and anti-hypertrophy effect on SM in a guinea pig asthma
model [26]. In mice chronic asthma models tiotropium
significantly decreased smooth muscle thickening and
peribronchial collagen deposition [69], with a reduction of
Th2-mediated cytokines such as Il4, IL5 and IL13, TGF-β
[69, 110]. The association of tiotropium and budesonide
or ciclesonide demonstrated to have inhibitory effects on
allergen-induced inflammation and remodeling in vivo, al-
though not in acute conditions [103, 104].
Mucus production
An increased mucus production is associated with lower
quality of life, less disease control and more exacerba-
tions, especially in smoker patients with asthma [111].
In healthy airways, MUC5AC is the most common
mucin gene normally produced, but its expression is
markedly increased in asthma and is mediated by M3R
which induce mucus production in goblet cells [112].
Selective M3R with tiotropium showed an inhibition of
neutrophil elastase-induce goblet cell metaplasia and
neutrophil-elastase induced MUC5AC production [113].
Concomitant administration of tiotropium and inhaled
steroids like budesonide [103] and dexamethasone [98]
showed to reduce allergen-induced mucus gland hyper-
trophy and mucus hyper secretion in mice models of
allergic asthma. Although having an effect on mucus
production, tiotropium was not demonstrated to alter
the rheological properties of mucus. The reported reduc-
tion of mucociliary clearance induced by the inhalation
of old antimuscarinic drugs and tertiary ammonium
compounds such as atropine was not reported after in-
halation of ipratropium or tiotropium [16].
Cough reflex
Although the number of studies investigating the modu-
lation of the cough reflex secondary to administration of
antimuscarinic compounds is raising, the majority of
them has been conducted in the 90’s and all showed a
reduction in cough threshold with administration of
ipratropium [114–118]. However, the disease models
used, the stimuli (mechanical, chemical) and the scale
employed to evaluate the cough response differ widely
[119] and thus the interpretation of the results appears
difficult. The evidences that studied the effects of tiotro-
pium are limited and mostly in animal models. In subjects
with upper viral respiratory tract infection tiotropium
after the first dose and after 7 days, with no correlation
with changes in pulmonary function, suggesting mecha-
nisms other than the modulation of the bronchomotor
tone [120]. Birrell and colleagues [121] showed that tiotro-
pium, but not glycopyrronium, was able to modulate the
cough reflex through the transient-potential vanilloid re-
ceptor type-1 (TRPV1) with mechanisms not related to its
anticholinergic activity, but rather interacting with another
binding site on the channel or by acting indirectly as a
modulator of the TRPV1 channel [121]. Further insight
was given by Mutolo and coworkers that suggested that
the down-regulation of cough promoted by tiotropium
implied also the involvement of acid-sensing ion channels
and mechanoreceptors [122].
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Dose finding
Children (6–11 years)
A summary of phase II trials that investigated dose finding
and safety of tiotropium in patients with uncontrolled
asthma is reported in Table 2.
Three different tiotropium Respimat® evening doses
(1.25 μg, 2.5 μg and 5 μg) were tested in a phase II
double-blind, placebo-controlled dose-ranging study in
children with symptomatic asthma despite a mainten-
ance therapy with medium-dose ICS with or without an
antileukotriene (LTRA). Patients’ mean (standard devi-
ation, SD) reversibility at screening was of 370 mL (171).
After 4 weeks of treatment, the peak FEV1 in the first
3 h (0–3 h) post-dose period (primary endpoint) was im-
proved by 87 mL (p = 0.0002), 104 mL (p < 0.0001) and
75 mL (p = 0.0011), for 5 μg, 2.5 μg and 1.25 μg re-
spectively compared with placebo, with no statistical
difference between doses. Similar significant improve-
ments and no dose-dependent response were observed
also for the mean trough FEV1 and the FEV1 area under
the curve (AUC) between 0 and 3 h post-dose (0–3 h).
All dosages improved the morning expiratory flow
(PEF) compared to placebo, while the improvement in
the evening PEF was limited to the highest dosage.
Although not different compared to placebo, asthma
control and quality of life were similarly improved, with a
comparable and low rate of adverse events (AEs) [123].
Adolescents (12–17 years)
A randomized, double-blind, placebo-controlled, incom-
plete crossover study evaluated once-daily tiotropium 5 μg,
2.5 μg and 1.25 μg delivered via Respimat® versus placebo
in three 4-week treatment periods; primary efficacy end
point was change in peak FEV1 (0–3 h). A significant im-
provement compared to placebo was found only for tiotro-
pium 5 μg (113 mL, p = 0.0043). Again, the largest and
only significant improvement compared to placebo for
trough FEV1 was found for tiotropium 5 μg (adjusted
mean: 151 mL; p < 0.0001). A slightly more frequent occur-
rence of AEs compared to other dosages and placebo was
present in patients treated with tiotropium 5 μg, while
serious AEs (4 in total, 1 in the tiotropium 5 μg group)
were not considered related to the study treatment [124].
Adults
Tiotropium 5 μg was demonstrated to be non-inferior to
the dosage of 10 μg and superior to placebo in terms of
lung function outcomes in a study involving patients
with uncontrolled severe asthma despite treatment with
high dose ICS/LABA [125]. The higher dose of tiotro-
pium, however, was associated with a higher rate of dry
mouth occurrence [125].
The pharmacokinetic profile of two regimens of in-
haled tiotropium, 2.5 μg twice daily (TD) and 5 μg once
daily (OD), was tested in a phase II randomized con-
trolled two way crossed over trial involving asthmatic
patients in maintenance therapy with budesonide 400–
800 μg or equivalent [126]. The geometric mean of pre-
dose plasma concentrations of tiotropium at steady state
ranged between 1.43 pg/mL (5 μg OD) and 1.59 pg/mL
(2.5 μg TD) [126], while the cumulative urinary excre-
tion over 24 h was similar for both dosing regimens
[126]. Accordingly, functional outcomes from Beeh et al.
[126] and Timmer et al. [127] demonstrated no difference
in FEV1AUC (0–24) for tiotropium 5 μg OD an d 2.5 μg
TD, while both dose regimens lead to a significant im-
provement compared to placebo [126, 127].
Efficacy and safety of three doses (namely 1.25 μg to
2.5 μg and 5 μg) of once-daily tiotropium Respimat®
were tested in a phase II, randomized, double-blind, pla-
cebo controlled, crossover study conducted in a popula-
tion of moderate asthma patients treated with stable
medium-dose ICS (400–800 μg budesonide or equivalent),
alone or in a fixed-dose combination with a LABA. Lung
function measured as peak FEV1 (0–3 h) improved for all
doses of tiotropium Respimat® (p < 0.0001 for all doses)
with a largest mean difference from placebo observed
for tiotropium 5 μg (188 mL, 95% confidence interval,
CI: 140, 236) [128].
Safety
Tiotropium long term safety as a primary outcome in
asthma patients was specifically evaluated in a 52-weeks
randomized controlled study in which tiotropium 5 μg,
2.5 μg and placebo were administered in symptomatic
Japanese patients as add-on therapy to ICS/LABA. The
most common AEs reported were nasopharyngitis
(48.2%, 44.7%, 42.1%), asthma (28.9%, 29.8%, 38.6%), de-
creased PEF (15.8%, 7.9%, 21.1%), bronchitis (9.6%,
13.2%, 7.0%), pharyngitis (7.9%, 13.2%, 3.5%) and gastro-
enteritis (10.5%, 3.5%, 5.3%) for 5 μg, 2.5 μg and placebo
respectively. The rate of serious adverse effects was slow
and not different between the study groups [129]. In the
majority of phase II and III trials that evaluated tiotro-
pium in asthma, patients with narrow angle glaucoma
and symptomatic prostatic hypertrophy were excluded;
nonetheless, considering the importance of such comor-
bidities in late onset asthma, the administration of tio-
tropium was not related to an increased frequency of
AEs involving the eye, reproductive and urinary tract ap-
paratuses. In the study conducted by Ohta et al. [129],
the frequency of AEs related to eye disorders was usually
very low, and lower in the tiotropium treated groups
compared to placebo (5.3 and 6.1 vs 8.8% for patients
treated with tiotropium 5 μg, 2.5 μg and placebo) [129].
In the same trial, cystitis was reported respectively by
4.4% (tiotropium 5 μg), 2.6% (tiotropium 2.5 μg) and
1.8% (placebo) of patients. A recent pooled analysis of
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randomized, double blind parallel group phase II and III
trials [130] investigated the safety profile of tiotropium
5 μg and 2.5 μg, compared to placebo. Out of 3,474 pa-
tients analyzed, 2,157 received tiotropium. The overall
percentage of patients reporting AEs was not different
between groups, being 60.8% vs 62.5% for tiotropium
5 μg and placebo 5 μg and 57.1% vs 55.1 for tiotropium
2.5 μg and placebo 2.5 μg. The most common AEs were
represented by a reduction in PEF and nasopharyngitis.
Adverse cardiac events were comparable between active
treatments and placebo. AEs typically associated with
use of LAMAs such as dry mouth was very low, ranging
from 0.4% for tiotropium 2.5 μg to 1.0% for tiotropium
5 μg. Serious AEs were similar between groups, albeit
slightly higher for 5 μg dose compared to 2.5 μg (4.0% vs
2.0%, respectively) [130].
Efficacy
Following proof of concept studies, the efficacy and safety
of tiotropium delivered via Respimat® was investigated in a
large scale clinical trial program (the UniTinA-asthma®)
and in many independent studies, which included chil-
dren, adolescents and adult patients. We summarized the
main findings of the RCTs published so far dividing them
by patients’ age (Table 3). If not differently stated, all
tiotropium doses are meant to be delivered by Respimat®
SofMist™ inhaler.
Children and adolescents
The efficacy of tiotropium was recently evaluated in pa-
tients <18 years old in four large, randomized double blind
placebo controlled studies. A phase III, parallel-group
52 weeks RCT compared tiotropium 5 μg (administered
by 2 inhalations of 2.5 μg), tiotropium 2.5 μg and placebo
Respimat® given in the evening in adolescent patients with
moderate symptomatic asthma. Symptomatic asthma was
defined as an ACQ-7 mean score of at least 1.5. Patients
had to be on maintenance therapy with ICSs, which was
permitted during the study, with or without a LABA or a
LTRA. Peak FEV1 (0–3 h) after 24 weeks was the primary
outcome. 376 patients completed the study. Peak FEV1
(0–3 h) was significantly and similarly improved for both
tiotropium doses (174 mL [95% CI, 76–272 mL] for
tiotropium 5 μg and 134 mL [95% CI,34–234 mL] for tio-
tropium 2.5 μg) compared with placebo. A rapid improve-
ment of the forced expiratory flow (FEF) between 25% and
75% of FVC (FEF25–75) compared with placebo was also
present beginning from 10 min post-dose for tiotropium
5 μg and 1 h post dose with the 2.5 μg dose. Trough FEV1
was significantly improved compared to placebo only for
tiotropium 5 μg: adjusted mean (standard error) 400 mL
(41), +117 mL (54) vs placebo, p = 0.03 [131]. The same
outcomes have been investigated by Hamelmann and
coworkers [132] in adolescent patients with severe
symptomatic asthma (ACQ-7 mean score of ≥1.5) des-
pite medium to high doses of ICS (from 400 μg to
1600 μg of budesonide or equivalent in patients aged
15–17 and >400 μg in those aged 12–14 years) and one
or more controller therapies (LABA and/or LTRA).
Peak FEV1 (0–3 h) compared with placebo was signifi-
cantly improved only with tiotropium 2.5 μg (111 mL;
p = 0.046), while all other outcomes, although showing
a trend towards improvement, were not met [132]. The
first and only phase III trial to assess the efficacy and
safety of once-daily tiotropium add-on therapy in chil-
dren with severe symptomatic asthma was published by
Szefler SJ and colleagues [133]. Patients had to be symp-
tomatic despite a maintenance therapy with medium ICS
with two or more controller medications or high dose ICS
with one or more controller medications and were ran-
domized to receive tiotropium 5 μg, 2.5 μg or placebo for
12 weeks. Compared with placebo, only add-on tiotro-
pium 5 μg significantly improved peak FEV1 (0–3)
(139 mL; 95% CI, 75–203), and trough FEV1 (87 mL; 95%
CI, 19–154) with a good safety profile [133].
The efficacy of tiotropium 18 μg administered by dry
powder inhaler was tested in children and adolescents
with moderate persistent asthma and compared with flu-
ticasone 125 μg via aerosol twice daily. After 12 weeks
of treatment, the tiotropium/fluticasone group experienced
significant improvements in FEV1, FVC and PEF and a re-
duced usage of SABA on demand therapy and night-time
symptoms compared with fluticasone alone [134].
Adults
Initial proof of concept studies were conducted between
late '90s and 2000 in adult asthmatic patients to prove
tiotropium efficacy in protecting from methacholine-
induced bronchoconstriction. O’Connor and colleagues
[86], using doses of 10 μg, 40 μg and 80 μg, demon-
strated that tiotropium was able to produce and main-
tain for 48 h a dose-dependent protection against
methacholine challenge at 2 h [mean (standard error):
5.0 (1.1); 7.1 (0.5) and 7.9 (0.7) doubling doses], despite
a mild increase in FEV1 that ranged between 5.5% and
11.1% from baseline [86]. Later on, Terzano and co-
workers showed that tiotropium at a dose of 18 μg de-
livered via HandiHaler® had a protective effect against
methacholine-induced bronchoconstriction in asthma
patients with airway hyper-responsiveness. In fact,
compared with placebo, patients treated with tiotro-
pium did not reach the provocative dose causing a
20% decrease in basal FEV1 [87]. Another double
blind, randomized, placebo controlled crossover study
investigated the possibility to introduce tiotropium in
order to step-down the ICS doses in severe asthma pa-
tients (mean FEV151% predicted). While in patients
treated with fluticasone 1000 μg + LABA lung function
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improvements were limited to PEF and airway resis-
tances, only patients treated with tiotropium 18 μg,
fluticasone 500 μg + LABA experienced also significant
improvements in FEV1 (+170 mL) and FVC (+240 mL)
which were associated also to a reduction in exhaled
nitric oxide by 2.86 ppb compared to placebo [135].
Iwamoto and colleagues demonstrated also that im-
provements in airway obstruction following adminis-
tration of tiotropium (dose not reported) in patients
with severe asthma were positively correlated with
neutrophil inflammation assessed by induced sputum,
suggesting that tiotropium would be more effective in
asthma patients with a non-eosinophilic phenotype [136].
The first large trial investigating the possibility to
introduce tiotropium in the regular treatment in patients
with uncontrolled asthma was the Tiotropium Bromide
as an Alternative to Increased Inhaled Glucocorticoid in
Patients Inadequately Controlled on a Lower Dose of
Inhaled Corticosteroid (TALC) study [137]. In 210 pa-
tients with moderate to severe uncontrolled asthma with
low doses of beclomethasone (80 μg daily), the investiga-
tors evaluated the addition of tiotropium 18 μg to beclo-
methasone 80 μg daily as compared with doubling the
dose of the ICS (primary superiority comparison) or
with the addition of salmeterol to beclomethasone 80 μg
(secondary non-inferiority comparison). The addition of
tiotropium to low-dose ICS resulted in significant im-
provements in all lung function and clinical outcomes
compared to doubling the ICS dosage. Compared to
the latter group, the association of tiotropium improved
both morning and evening PEF were improved with
tiotropium (+25.8 l/min; 95% CI, 14.4–37.1;p < 0.001
and +35.3 l/min; 95% CI, 24.6 – 46.0; p < 0.001, respect-
ively), the pre-dose FEV1 (+100 mL, p = 0.004), the pro-
portion of asthma-control days, score for daily
symptoms, and the ACQ-7 (−0.18 points; p = 0.02).
Moreover, tiotropium add-on therapy resulted to be
non inferior to the LABA/ICS association in all out-
comes [137]. Confirmatory results came from a single-
center study in which treatment with tiotropium +
LABA + low dose ICS was non inferior in functional
outcomes and nitric oxide reduction to LABA + double
dose ICS in patients with uncontrolled asthma [138].
Subsequently, two replicate, randomized, placebo-
controlled 48-week period trials (PrimoTinA-asthma 1
and PrimoTinA-asthma 2) were designed to specifically
assess if tiotropium 5 μg add on therapy to high dose
ICS + LABA compared to add-on placebo was effective
in improving disease control both in terms of lung func-
tion [peak FEV1 (0–3 h) and through FEV1] and of time
to first exacerbation in patients poorly controlled with
maintenance therapy [139]. Patients had to have a
FEV1 < 80% predicted and a history of at least 1 severe
asthma exacerbation in the previous year. Change in
peak FEV1 (0–3 h) from baseline was significantly
greater with tiotropium than with placebo in both trials
(vs placebo, mean ± SE: 86 ± 34 mL and 154 ± 32 mL),
and this was true also for the trough FEV1 (vs placebo:
88 ± 31 mL and 111 ± 30 mL). Time to the first severe
exacerbation was increased in patients treated with
add-on tiotropium (282 days vs. 226 days), with an
overall reduction of 21% in the risk of a severe exacer-
bation (hazard ratio: 0.79; p = 0.03) [139]. The response
to treatment with tiotropium was shown to be independent
of baseline characteristics including gender, age, body mass
index, disease duration, age at asthma onset, FEV1% pre-
dicted at screening and reversibility [140].
The non inferiority of tiotropium compared to LABA
as add-on therapy to ICS in patients with moderate
asthma was investigated in two 24-week, replicate, ran-
domized, double-blind, placebo-controlled, parallel-group,
active comparator trials (MezzoTinA-asthma 1 and
MezzoTinA-asthma 2) [141]. These two parallel trials ran-
domized a total of 2,103 patients to receive tiotropium
5 μg OD, tiotropium 2.5 μg OD, salmeterol 50 μg BID or
placebo on top of maintenance therapy with medium dose
budesonide (400–800 μg). Again, the two functional co-
primary end-points were peak FEV1 (0–3 h) and through
FEV1 at the end of the 24-week treatment period, addi-
tionally, the study assessed the proportion of responders
by means of the ACQ-7, i.e. patients that increased the
ACQ-7 score more than 0.5. Pooled data of the 1,972 pa-
tients that completed the studies showed significant im-
provements for both doses of tiotropium and salmeterol
compared to placebo in all functional outcomes. Com-
pared to placebo, both doses of tiotropium and salmeterol
significantly improved peak FEV1 (0–3 h) and trough
FEV1, although results were numerically higher for tiotro-
pium 2.5 μg. There were more ACQ-7 responders in the
tiotropium 5 μg (OR 1.32; 95% CI: 1.02–1.71; P = 0.035),
2.5 μg (1.33; 95% CI: 1.03–1.72; P = 0.031) and the salme-
terol group (1.46, 95% CI: 1.13–1.89; p = 0.0039), com-
pared to placebo. Although median time to first severe
exacerbation could not be calculated because less than
50% of patients in each treatment group had one or more
severe exacerbations, a statistically significant reduction in
risk of first severe exacerbation was reported for tiotro-
pium 2.5 μg and of first asthma worsening for tiotropium
2.5 μg and salmeterol [141]. A recent phase III RCT com-
pared tiotropium 2.5 μg and 5 μg OD versus placebo as
add-on therapy to maintenance treatment with ICS in pa-
tients with moderate symptomatic asthma with a FEV1 of
60 to 90% predicted. Data from 464 patients were ana-
lyzed. After 12 weeks of treatment, both dose regimens
showed superiority over placebo in terms of through
FEV1and peak FEV1 (0–3 h); however, numerically better
results for peak FEV1 (0–3 h) and FEV1AUC (0–3 h) were
found for tiotropium 2.5 μg compared to 5 μg [adjusted
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mean (SE): 293 mL (26) vs 262 mL (26) and 198 mL (24) vs
174 mL (25), respectively]. The frequency of AEs was not
different across the treatment regimens [142].
These large studies demonstrated the efficacy of tiotro-
pium as add-on therapy both to moderate-to-high dose
of ICS and to ICS/LABA maintenance therapy in terms of
lung function, risk of exacerbation and disease worsening,
goals that were achieved with a safety profile similar to
LABA comparators and placebo. Further post hoc analyses
of pooled data from MezzoTinA-asthma 1, MezzoTinA-
asthma 2, PrimoTinA-asthma 1 and PrimoTinA-asthma 2
suggested that the efficacy of tiotropium was independent
of underlying allergic/eosinophilic inflammation and thus
of the T-helper 2 asthma phenotype, as outcomes were
reached in patients with a broad range of IgE and eosino-
phil values [143].
The Arg16/Arg16 β2-adrenergic receptors polymorphism
represents a common finding both in African Americans
(20%) and Caucasians (15%) [59] and is associated with a
blunted sensitivity to the maintenance asthma treatment
with SABAs thus justifying a worse disease control with
long term treatment with ICS/LABA FDC both in adults
[144] and in children [145]. This assumption led to investi-
gate the predictors of response to therapy by means of a
pharmacogenetic approach. Sequencing of eleven different
nucleotide polymorphisms was performed in 138 asthmatic
not controlled with their maintenance therapy in which tio-
tropium 18 μg was added once daily. The positive response
to tiotropium in terms of lung function was found in 33%
of patients and was predicted by the Arg16Gly polymorph-
ism [146]. When a cohort of asthmatic patients homozy-
gous for the Arg16 β2 adrenergic receptor polymorphism
were prospectively studied, tiotropium demonstrated to be
non inferior to salmeterol in improving the morning PEF
(mean ± SD; −3.9 ± 4.87 L/min for tiotropium and −3.2 ±
4.64 L/min for salmeterol) [147]. Given the proportion of
African-American patients with allelic variations associated
with poor asthma control, a study specifically powered and
designed to assess the risk of exacerbations in this
particular population was set in 2011. The Blacks and
Exacerbations on LABA vs Tiotropium (BELT study)
[148] was a parallel-group, randomized pragmatic trial
that enrolled black adults with asthma from primary
care and specialty practices in the United States. Par-
ticipants were enrolled if on step 3 or step 4 combin-
ation ICS and LABA therapy, and were randomized
to receive a LABA (salmeterol or formoterol) or tio-
tropium in addition to their chronic dose of ICS. The
primary outcome was time to asthma exacerbation,
secondary outcomes included patient-reported out-
comes, lung function (FEV1 changes), rescue medica-
tion use and AEs. The investigators found no
Fig. 1 Possible role of tiotropium bromide in the management of asthma. The colour code refers to the functional and clinical characteristics that
tiotropium should be able to modify according to its pharmacological properties. If the effect on functional and clinical asthma domains is effected
prevalently by specific tiotropium properties, the effect on asthma control and future risk might be modulated by the concomitant action of different
characteristics taken together. Th2, T helper-2 lymphocytes; SM, smooth muscle cells; MUC5AC, mucin-5 subtype AC gene; QoL, Quality of Life; ACQ-7,
Asthma Control Questionnaire
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difference between the two treatment regimens in
terms of primary and secondary outcomes. Neither of
the Arg16Gly β2-adrenergic receptors alleles was as-
sociated with differences in the effects of tiotropium
+ ICS vs LABA + ICS [148].
Initial validations of these RCTs in real life settings
can be found in two recent retrospective studies. An
analysis of 64 patients with poor disease control despite
treatment with high dose ICS/LABA showed that the
introduction of tiotropium as add on therapy improved
asthma control in 42.2% of cases, decreasing the number
of emergency department visits and hospitalizations in
46.9% and 50.0% of cases, respectively [149]. A larger co-
hort involving 2,042 outpatients from United Kingdom
compared the number of exacerbations (emergency
visits, hospitalizations and oral corticosteroids use) and
acute asthma events (antibiotic use for lower respiratory
tract infections) in the year before and in the year fol-
lowing the prescription of tiotropium. Patients experi-
enced an overall significant decrease in exacerbations
and acute asthma events by 10% and 11%; however,
there was a significant increase in the as needed usage of
SABA from a median (IQR) of 274 (110–548) to 329
(110–603) μg/day [150].
Conclusions
Asthma control represents the main goal of numerous
respiratory societies worldwide and a lot of energy has
been spent so far trying to change quality of life of
patients with uncontrolled asthma. Beside patient
dependent factors, advances in maintenance therapy
represent one of the cornerstones of risk management
and disease control. Following its proven efficacy and
safety in patients with COPD, a large body of evidence
is now available for the use of tiotropium also in pa-
tients with poor controlled asthma. Large RCTs per-
formed with patients with moderate to severe asthma
have demonstrated its efficacy in improving lung func-
tion, decreasing risk of exacerbation and slowing the
worsening of disease as add-on therapy, and its non in-
feriority compared to LABAs along the ICS mainten-
ance treatment. In view of the ancillary and the
synergistic effects provided by the cross-talk between
β2 and muscarinic receptors, tiotropium can represent
a beneficial alternative in the therapeutic management
of poor controlled asthma (Fig. 1). Tiotropium safety
profile and the broad spectrum of efficacy demon-
strated in different disease phenotypes allows its use
also in the pediatric and allergic population. More studies
in human models of asthma are needed to explore its in-
vivo anti-inflammatory effects, its impact on lung volumes
and airway resistances and thus its role as disease modifier
in the natural history of asthma.
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